Trial Profile
A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Nov 2013
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacodynamics
- Sponsors Dainippon Sumitomo Pharma
- 17 Nov 2013 New trial record
- 09 Oct 2013 Efficacy and tolerability results from a pooled analysis presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.